Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Next Previous
X
Search
Trial Profile

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
    • 19 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Nov 2017 According to a Celldex Therapeutics media release, were presented at the 9th World Congress of Melanoma in October 2017 by the National Cancer Institute (NCI)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top